Zoetis Inc. (NYSE:ZTS) Shares Acquired by PDT Partners LLC

PDT Partners LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 61.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,061 shares of the company’s stock after purchasing an additional 6,461 shares during the quarter. PDT Partners LLC’s holdings in Zoetis were worth $3,333,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Mizuho Securities USA LLC grew its position in shares of Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after acquiring an additional 4,829,815 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Zoetis by 4.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after purchasing an additional 178,303 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Zoetis by 5.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock worth $761,221,000 after purchasing an additional 194,542 shares during the last quarter. Clearbridge Investments LLC increased its stake in shares of Zoetis by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after purchasing an additional 166,517 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in shares of Zoetis by 17.3% during the third quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock valued at $464,497,000 after buying an additional 351,372 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 0.8 %

Shares of NYSE:ZTS opened at $175.25 on Friday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a market capitalization of $79.07 billion, a price-to-earnings ratio of 32.94, a PEG ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The company has a 50 day moving average price of $183.83 and a 200 day moving average price of $180.84.

Zoetis (NYSE:ZTS) last issued its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the previous year, the firm posted $1.36 EPS. The company’s quarterly revenue was up 11.6% on a year-over-year basis. On average, research analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a dividend yield of 0.99%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is 32.52%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus raised their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. BTIG Research upped their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. upped their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.